120 related articles for article (PubMed ID: 17851243)
1. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
Krook AL; Stokka D; Heger B; Nygaard E
Eur Addict Res; 2007; 13(4):216-21. PubMed ID: 17851243
[TBL] [Abstract][Full Text] [Related]
2. [Quality assurance in patient addiction treated with drug substitution].
Krankenpfl J; 2005; 43(7-10):248. PubMed ID: 16515317
[No Abstract] [Full Text] [Related]
3. [Treatment of chronic hepatitis C within a heroine-assisted treatment program].
Deibler P; Haasen C; Reimer J
Dtsch Med Wochenschr; 2006 Dec; 131(50):2835-7. PubMed ID: 17160765
[TBL] [Abstract][Full Text] [Related]
4. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534
[TBL] [Abstract][Full Text] [Related]
5. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
6. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
Schaefer M; Mauss S
Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
[TBL] [Abstract][Full Text] [Related]
8. Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Matthews AM; Fireman M; Zucker B; Sobel M; Hauser P
Am J Psychiatry; 2006 Aug; 163(8):1342-7; quiz 1479. PubMed ID: 16877644
[No Abstract] [Full Text] [Related]
9. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.
Litwin AH; Berg KM; Li X; Hidalgo J; Arnsten JH
BMC Infect Dis; 2011 Nov; 11():315. PubMed ID: 22078241
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
11. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
Mauss S; Berger F; Goelz J; Jacob B; Schmutz G
Hepatology; 2004 Jul; 40(1):120-4. PubMed ID: 15239094
[TBL] [Abstract][Full Text] [Related]
12. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment.
Berk SI; Litwin AH; Arnsten JH; Du E; Soloway I; Gourevitch MN
Clin Ther; 2007 Jan; 29(1):131-8. PubMed ID: 17379053
[TBL] [Abstract][Full Text] [Related]
13. [Difficult-to-treat patients with chronic hepatitis C].
Zeuzem S
Praxis (Bern 1994); 2006 Sep; 95(38):1459-64. PubMed ID: 17058596
[TBL] [Abstract][Full Text] [Related]
14. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.
Litwin AH; Harris KA; Nahvi S; Zamor PJ; Soloway IJ; Tenore PL; Kaswan D; Gourevitch MN; Arnsten JH
J Subst Abuse Treat; 2009 Jul; 37(1):32-40. PubMed ID: 19038524
[TBL] [Abstract][Full Text] [Related]
16. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.
Sylvestre DL; Clements BJ
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):741-7. PubMed ID: 17700258
[TBL] [Abstract][Full Text] [Related]
17. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
18. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.
Huber M; Weber R; Oppliger R; Vernazza P; Schmid P; Schönbucher P; Bertisch B; Meili D; Renner EL
Infection; 2005 Feb; 33(1):25-9. PubMed ID: 15750756
[TBL] [Abstract][Full Text] [Related]
19. [Buprenorphine and methadone to opiate addicts--a randomized trial].
Kristensen Ø; Espegren O; Asland R; Jakobsen E; Lie Ø; Seiler S
Tidsskr Nor Laegeforen; 2005 Jan; 125(2):148-51. PubMed ID: 15665884
[TBL] [Abstract][Full Text] [Related]
20. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
